Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart induction and maintenance study in moderately to severely active Crohn's disease
NL-OMON59163Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Afimkibart with Placebo (2 arms). Primary endpoints: Clinical remission and Endoscopic response. Started Jul 2025; status: recruiting.
02
Drugs
afimkibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON59163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59163.